Therefore, the finding of enhanced M2 macrophage infiltration in the high CCL2 expression group suggested a potential mechanism by which CCL2 may contribute to tumor progression and therapeutic resistance in the recurrent GBM. This evidence concerns the gene CCL2 and glioblastoma.